TrumpRx: Comprehensive Overview
TrumpRx: Comprehensive Overview
Drug Pricing, Company Deals, Beneficiaries & Comparison to Cost Plus Drugs
Published: February 6, 2026 | Source: Lodi411.com Research
Executive Summary
On February 5, 2026, the Trump administration launched TrumpRx.gov, a government-hosted website offering discounted cash prices on 43 brand-name medications from five pharmaceutical companies, with 11 more companies expected soon. The platform operates under a Most-Favored-Nation (MFN) pricing model—ensuring U.S. consumers pay no more than the lowest prices charged in other wealthy nations. TrumpRx does not sell drugs directly; instead, it provides coupons or links to manufacturers' direct-to-consumer sites.
Experts note the platform primarily benefits uninsured Americans and those whose medications aren't covered by insurance (e.g., weight-loss drugs, fertility treatments). For the roughly 84% of Americans with prescription drug coverage, insurance copays are likely to remain cheaper than TrumpRx cash prices for most medications.
How TrumpRx Works
TrumpRx.gov functions as a centralized coupon hub built with technology from GoodRx. Patients search for their medication, then either print a discount coupon to present at a pharmacy or click through to a manufacturer's direct-to-consumer website (e.g., Novo Nordisk's NovoCare or Eli Lilly's LillyDirect) to complete the purchase. A valid prescription is required.
Key Mechanism: Most-Favored-Nation (MFN) Pricing — In exchange for exemptions from certain U.S. tariffs, pharmaceutical companies agreed to: (1) offer discounted cash prices on TrumpRx, (2) lower prices for Medicaid programs, and (3) launch future new drugs in the U.S. at prices no higher than those in peer nations.
Important limitations: TrumpRx discounted pricing is only available for cash-paying patients. Insurance is not accepted. Purchases through TrumpRx generally do not count toward insurance deductibles or out-of-pocket maximums.
Companies & Drugs Involved
Live at Launch (5 Companies)
| Company | Key Drugs | Conditions Treated |
|---|---|---|
| Novo Nordisk | Ozempic, Wegovy (injection & pill) | Diabetes, obesity, heart disease |
| Eli Lilly | Zepbound, Trulicity | Obesity, diabetes |
| Pfizer | 30+ medications including Xeljanz, Protonix | Autoimmune, GERD, various |
| AstraZeneca | Bevespi and others | COPD, respiratory |
| EMD Serono | Gonal-F, Cetrotide | Fertility / IVF treatments |
Signed MFN Deals — Coming Soon (11+ Companies)
| Company | Notable Commitments |
|---|---|
| Bristol Myers Squibb | Free Eliquis (blood thinner) for Medicaid patients; ~80% price cuts on DTC drugs |
| Amgen | Aimovig (migraine) & Amjevita (autoimmune) at $299/mo; Repatha (cholesterol) |
| Merck & Co. | Januvia (diabetes) expected at $100/mo |
| Genentech | Committed to lowering drug costs for patients |
| Gilead Sciences | MFN pricing agreement signed |
| GlaxoSmithKline | MFN pricing agreement signed |
| Novartis | MFN pricing agreement signed |
| Sanofi | MFN pricing agreement signed |
| Boehringer Ingelheim | MFN pricing agreement signed |
TrumpRx Drug Prices vs. List Prices
| Drug | Condition | List Price | TrumpRx Price | Discount |
|---|---|---|---|---|
| Ozempic (injection) | Diabetes | $1,028/mo | $199–$350/mo | 66–81% |
| Wegovy (injection) | Obesity | $1,349/mo | $199–$349/mo | 74–85% |
| Wegovy Pill | Obesity | $1,349/mo | $149–$299/mo | 78–89% |
| Zepbound (injection) | Obesity | $1,087/mo | $299–$449/mo | 59–72% |
| Trulicity | Diabetes | ~$989/mo | $389/mo | ~61% |
| Gonal-F | Fertility / IVF | $1,449/pen | $252/pen | 83% |
| Cetrotide | Fertility / IVF | Full price | Deeply discounted | 93% |
| Xeljanz (Pfizer) | Autoimmune | Full price | Discounted | 33% |
| Protonix (Pfizer) | GERD / Heartburn | Full price | ~$200/mo | Varies |
GLP-1 Drug Prices: List Price vs. TrumpRx
TrumpRx prices shown are lowest available starting doses. List prices are manufacturer retail prices.
Who Benefits from TrumpRx?
✓ Most Likely to Benefit
Uninsured Americans (~27 million people without prescription drug coverage) who previously paid full list prices for brand-name drugs.
Patients needing uncovered drugs — especially GLP-1 weight-loss medications and IVF fertility treatments, which many employer plans don't cover. The fertility drug discounts alone could reduce IVF cycle costs by ~20%.
High-deductible plan enrollees who haven't met their deductible and face full list prices at the pharmacy counter.
✗ Unlikely to Benefit
84% of Americans with prescription drug coverage will generally find insurance copays cheaper than TrumpRx cash prices.
Generic drug users — 9 out of 10 U.S. prescriptions are generics, which TrumpRx doesn't offer. Some brand-name drugs on TrumpRx have cheap generic equivalents (e.g., Protonix at $200 vs. generic pantoprazole at $30).
Medicare Part D enrollees often pay less through negotiated Medicare prices. TrumpRx purchases don't count toward the Part D $2,100 annual out-of-pocket cap.
TrumpRx Prices vs. Insurance Coverage
The discounts displayed on TrumpRx are measured against list prices, but most insured Americans never actually pay list price. After rebates, deductibles, and negotiated rates, out-of-pocket costs through insurance are typically much lower.
Employer-Sponsored Insurance
Most insured patients pay copays of $10–$75/month for preferred brand-name drugs after meeting deductibles. Once deductibles are satisfied, copays drop far below TrumpRx cash prices. Insurers and pharmacy benefit managers (PBMs) negotiate significant discounts that individual cash-pay patients cannot access.
Exception: Many employer plans still don't cover obesity drugs. For those patients, $199–$349/month for Wegovy via TrumpRx is a dramatic improvement over $1,349 out of pocket.
Medicare
Medicare Part D has its own negotiated prices through the Biden-era Inflation Reduction Act Drug Price Negotiation Program, plus the new MFN deals. Key comparisons:
- Ozempic: Medicare-negotiated MFP = $274/mo vs. MFN Medicare price = $245/mo (MFN is slightly better)
- Eliquis: Medicare-negotiated MFP = $231/mo vs. TrumpRx consumer price = $346/mo (Medicare is cheaper)
- Obesity drugs: Under Lilly/Novo deals, Medicare beneficiaries will pay just $50/month copays — far below TrumpRx cash prices
Medicare Part D now caps annual out-of-pocket spending at $2,100. Cash purchases through TrumpRx do not count toward this cap.
Medicaid
Medicaid already receives discounts exceeding 75% off list prices according to CBO studies, and beneficiaries pay minimal or zero copays. The broader MFN deals extend favorable pricing to Medicaid—for example, Bristol Myers Squibb will provide Eliquis to Medicaid recipients for free. TrumpRx's cash-pay model isn't designed for Medicaid patients, but the accompanying MFN agreements directly reduce what Medicaid programs pay.
Monthly Cost by Coverage Type: Select Drugs
Insurance copays shown are typical ranges after deductible. Medicare prices reflect negotiated MFP or MFN. Medicaid copays are $0–$4 in most states.
TrumpRx vs. Cost Plus Drugs
These two platforms serve fundamentally different segments of the prescription drug market. In late 2025, Cost Plus Drugs and TrumpRx announced a partnership in which Cost Plus shares its API so TrumpRx can pull pricing data, increasing price transparency for consumers.
| Feature | TrumpRx | Cost Plus Drugs |
|---|---|---|
| Drug Type | Brand-name only | Primarily generics (~2,300+) |
| Pricing Model | MFN cash-pay discounts | Manufacturer cost + 15% markup + $5 pharmacy + $5 shipping |
| Insurance Accepted | No — cash-pay only | Yes — 24+ insurance providers |
| Number of Drugs | ~43 at launch (expanding) | 2,300+ medications |
| How It Works | Coupon hub linking to manufacturer DTC sites | Online pharmacy that ships drugs |
| Best For | Uninsured needing expensive brand-name drugs | Anyone needing affordable generics |
| Deductible Credit | Generally does not count | Depends on insurance provider |
| Operator | U.S. Government (via GoodRx tech) | Private company (Mark Cuban) |
Platform Comparison: Drug Selection & Insurance
Cost Plus Drugs offers far more medications overall, primarily generics. TrumpRx focuses on high-cost brand-name drugs.
Key Insight: The two platforms are largely complementary, not competitive. Cost Plus Drugs excels at making affordable generics even cheaper, while TrumpRx targets expensive patented brand-name drugs with no generic equivalent—such as GLP-1 weight-loss medications. For a drug like Protonix (GERD), TrumpRx lists it at $200/month while the generic version (pantoprazole) is available for about $30 through GoodRx or Cost Plus. But for Wegovy or Zepbound, where no generic exists, TrumpRx fills a gap Cost Plus cannot.
Expert Analysis & Key Takeaways
- Narrow but real benefit: TrumpRx represents a meaningful step for uninsured Americans and those needing medications their insurance won't cover, particularly weight-loss drugs and IVF treatments.
- Limited impact for most Americans: For the 84% with prescription drug coverage, insurance copays will generally remain cheaper than TrumpRx cash prices. One health economist called the direct-to-consumer platform a "sideshow and branding opportunity."
- Deductible trap: Cash purchases through TrumpRx typically don't count toward insurance deductibles or out-of-pocket maximums, potentially costing insured patients more in the long run.
- The broader MFN deals matter more: The Medicaid price reductions and Medicare copay caps ($50/month for GLP-1s) negotiated as part of the MFN agreements are arguably more consequential for the majority of Americans than the TrumpRx website itself.
- Price transparency is valuable: The Cost Plus partnership and aggregation of manufacturer coupons in one place gives consumers a useful comparison tool, even if the prices themselves aren't always the best option.
- Ongoing expansion: With 11 more pharmaceutical companies set to add drugs in coming months, the platform's utility could grow—particularly as Express Scripts has agreed to eventually count TrumpRx purchases toward deductibles.
References & Sources
- TrumpRx.gov — Official TrumpRx platform
- White House Fact Sheet: TrumpRx Launch (February 5, 2026)
- White House Fact Sheet: MFN Pricing Developments (November 6, 2025)
- CNBC: White House Launches Direct-to-Consumer Drug Site TrumpRx (February 5, 2026)
- NBC News: Trump Launches Discount Drug Platform (February 5, 2026)
- ABC News: Trump Unveils TrumpRx Website (February 5, 2026)
- CNN: TrumpRx Set to Launch (February 5, 2026)
- NPR: TrumpRx Drug Discounts (February 5, 2026)
- STAT News: What to Know About TrumpRx (February 5, 2026)
- CBS News: White House Launches TrumpRx (February 5, 2026)
- Pharmacy Times: Every MFN Agreement Roundup (February 2026)
- AJMC: TrumpRx Launch Brings Savings and Uncertainty (February 5, 2026)
- Georgetown Medicare Policy: Drug Pricing in the Era of Trump 2.0
- Healthline: TrumpRx and GLP-1 Drug Costs (November 2025)
- Al Jazeera: TrumpRx Website Launches (February 6, 2026)